S obzirom na to da je za potpuno razumijevanje bioloških sustava nužna i molekularna karakterizacija proteoma, proteomika je disciplina koja je nastala sa svrhom da komplementira istraživanje genoma. Iako je proteomika relati vno nova biološka znanstvena disciplina, ona ima velik potencijal u farmaceutskoj industriji. Različite tehnike proteomike stoga se koriste u svrhu razjašnjavanja molekularnih mehanizama koji upravljaju staničnim procesima, za
karakterizaciju složenih proteinskih mreža u stanici, za otkrivanje proteina biomarkera te, naposljetku, za identifikaciju novih meta za razvoj novih lijekova. Upravo u razvoju protutumorskih lijekova proteomika može omogućiti identi fi kaciju proteina uključenih u patogenezu raka, a rekonstrukcija signalnih putova može olakšati otkrivanje novih meta na koje bi novi lijek djelovao, te omogućiti uvid u mehanizme djelovanja ti h lijekova, kao i njihovu toksičnost.The fi eld of proteomics has been thought as complementary to the genomic research since proteins are the executi ve molecules and players in biological systems. In particular, protein functionality is highly deregulated in cancer. Although proteomics is a relatively new research area it holds great potential in pharmaceutical industry due to its ability to quantitatively measure protein expression and identi fy proteins by mass spectrometry analyses as well as its ability to map the protein-protein interacti ons. As such, the proteomics
technological platf orm has been widely applied to basic cancer research, cancer therapy and most importantly in the drug discovery process. Proteomics allows identi fi cati on of proteins involved in cancer pathogenesis and deregulated signalling pathways that facilitates the discovery of new drug targets, or it might be used as well to precisely elucidate the drug mechanisms of acti on and toxicology
